Preparation and characterization of a nanovaccine of pVAX1-NH36 for leishmaniasis

[1]  R. Löbenberg,et al.  Promising nanotherapy in treating leishmaniasis. , 2018, International journal of pharmaceutics.

[2]  V. B. Richini-Pereira,et al.  Human leishmaniasis in Brazil: A general review. , 2018, Revista da Associacao Medica Brasileira.

[3]  M. Ghorbani,et al.  Leishmaniasis in humans: drug or vaccine therapy? , 2017, Drug design, development and therapy.

[4]  M. Schmeer,et al.  Plasmid DNA Manufacturing for Indirect and Direct Clinical Applications. , 2017, Human gene therapy.

[5]  J. Moreno,et al.  F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis , 2017, Front. Immunol..

[6]  D. Vashaee,et al.  Development of a DNA-liposome complex for gene delivery applications. , 2017, Materials science & engineering. C, Materials for biological applications.

[7]  T. Furuno,et al.  Gene transfection efficiency into dendritic cells is influenced by the size of cationic liposomes/DNA complexes , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  A. Morrot,et al.  Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis , 2017, Front. Immunol..

[9]  J. Ortega-López,et al.  Plasmid pVAX1-NH36 purification by membrane and bead perfusion chromatography , 2017, Bioprocess and Biosystems Engineering.

[10]  Yanhang Hong,et al.  Polymers for DNA Vaccine Delivery. , 2017, ACS biomaterials science & engineering.

[11]  P. Michels,et al.  Nanotechnological Strategies for Treatment of Leishmaniasis--A Review. , 2017, Journal of biomedical nanotechnology.

[12]  Jessica Jimenez,et al.  Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys , 2016, Science.

[13]  Maria Elena Bottazzi,et al.  Status of vaccine research and development of vaccines for leishmaniasis. , 2016, Vaccine.

[14]  M. Samant,et al.  DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control , 2016, Parasite immunology.

[15]  A. Pannier,et al.  Micro- and nanoparticulates for DNA vaccine delivery , 2016, Experimental biology and medicine.

[16]  Laura M Ensign,et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.

[17]  N. Petrovsky,et al.  Molecular mechanisms for enhanced DNA vaccine immunogenicity , 2016, Expert review of vaccines.

[18]  P. Hotez,et al.  New Vaccines for the World's Poorest People. , 2016, Annual review of medicine.

[19]  T. A. Balbino,et al.  Physicochemical and in vitro evaluation of cationic liposome, hyaluronic acid and plasmid DNA as pseudo-ternary complexes for gene delivery , 2015 .

[20]  K. Jain,et al.  Vaccines for visceral leishmaniasis: A review. , 2015, Journal of immunological methods.

[21]  K. Prather,et al.  Towards effective non-viral gene delivery vector , 2015, Biotechnology & genetic engineering reviews.

[22]  A. Aruga,et al.  Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan , 2015, Vaccines.

[23]  Anurag S. Rathore,et al.  Application of process analytical technology for downstream purification of biotherapeutics , 2015 .

[24]  S. Ulbert,et al.  Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases , 2015, Clinical and experimental vaccine research.

[25]  Priyabrata Pattnaik,et al.  Production and purification of plasmid DNA vaccines: is there scope for further innovation? , 2014, Expert review of vaccines.

[26]  Atul Kolate,et al.  PEG - a versatile conjugating ligand for drugs and drug delivery systems. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[27]  K. Prather,et al.  Plasmid DNA production with Escherichia coli GALG20, a pgi-gene knockout strain: fermentation strategies and impact on downstream processing. , 2014, Journal of biotechnology.

[28]  Mi Young Lee,et al.  Nanoparticles for gene delivery: therapeutic and toxic effects , 2014, Molecular & Cellular Toxicology.

[29]  A. Satoskar,et al.  Mechanisms of cellular invasion by intracellular parasites , 2014, Cellular and Molecular Life Sciences.

[30]  Kristala L J Prather,et al.  Engineering of Escherichia coli strains for plasmid biopharmaceutical production: scale-up challenges. , 2014, Vaccine.

[31]  Alvaro R. Lara,et al.  Effect of growth rate on plasmid DNA production and metabolic performance of engineered Escherichia coli strains. , 2014, Journal of bioscience and bioengineering.

[32]  E. Dumonteil,et al.  Production optimisation of a DNA vaccine candidate against leishmaniasis in flask culture , 2013 .

[33]  M. Rito‐Palomares,et al.  DNA based vaccines offer improved vaccination supply for the developing world , 2013 .

[34]  W. Lindner,et al.  Chemoaffinity material for plasmid DNA analysis by high-performance liquid chromatography with condition-dependent switching between isoform and topoisomer selectivity. , 2013, Analytical chemistry.

[35]  I. Correia,et al.  Nanoparticle mediated delivery of pure P53 supercoiled plasmid DNA for gene therapy. , 2011, Journal of Controlled Release.

[36]  D. Weiner,et al.  DNA vaccines in veterinary use , 2009, Expert review of vaccines.

[37]  S. Takeoka,et al.  Plasmid DNA-encapsulating liposomes: effect of a spacer between the cationic head group and hydrophobic moieties of the lipids on gene expression efficiency. , 2009, Biochimica et biophysica acta.

[38]  K. Taylor,et al.  A calorimetric study of dimyristoylphosphatidylcholine phase transitions and steroid-liposome interactions for liposomes prepared by thin film and proliposome methods. , 2006, International journal of pharmaceutics.

[39]  W. Buchinger,et al.  Industrial Scale cGMP Purification of Pharmaceutical Grade Plasmid‐DNA , 2005 .

[40]  M. M. Diogo,et al.  Assessment of purity and quantification of plasmid DNA in process solutions using high-performance hydrophobic interaction chromatography. , 2003, Journal of chromatography. A.

[41]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[42]  A. Myhr.  DNA Vaccines: Regulatory Considerations and Safety Aspects. , 2017, Current issues in molecular biology.

[43]  M. Kavitha,et al.  OVERVIEW OF VALIDATION, BASIC CONCEPTS AND ANALYTICAL METHOD PROCESS VALIDATION , 2017 .

[44]  Natalia Dzięgiel.  Nanoparticles as a Tool for Transfection and Transgenesis – a Review , 2016 .

[45]  Prasad Kanuri.  SCIENCE AND RISK BASED APPROACH TO THE PROCESS VALIDATION – LINK FROM QUALITY BY DESIGN TO PROCESS VALIDATION , 2016 .

[46]  J. S. Dua,et al.  LIPOSOME: METHODS OF PREPARATION AND APPLICATIONS , 2012 .